Abstract
COVID-19 is an ongoing global pandemic of coronavirus disease 2019 as an atypical type of viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV 2). Many potential pharmacological agents are currently being investigated against this disease. This article points to, and justifies, the importance of investigating the potential pharmacotherapies for COVID-19 “pneumonia”, rather than the broad category of COVD-19 disease, or COVID-19 associated acute respiratory distress syndrome (ARDS).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
